Welcome to our dedicated page for ReShape Lifesciences news (Ticker: RSLS), a resource for investors and traders seeking the latest updates and insights on ReShape Lifesciences stock.
ReShape Lifesciences Inc. (RSLS) reported company developments tied to weight loss and metabolic health products for obesity and metabolic disease. Its product references include the FDA-approved Lap-Band System for minimally invasive obesity treatment, the investigational Diabetes Bloc-Stim Neuromodulation system using vagus nerve block and stimulation technology for type 2 diabetes and metabolic disorders, and Obalon balloon technology for a swallowable intragastric balloon approach.
Recurring RSLS news categories include clinical and regulatory disclosures, intellectual-property updates for intragastric balloon systems, surgeon education around Lap-Band, shareholder voting matters, governance items, material agreements, security-structure disclosures, and capital-structure actions.
ReShape Lifesciences Inc. (OTCQB:RSLS) announced it will reveal its second quarter 2020 financial results on August 13, 2020, after U.S. market close. A webinar led by management will follow at 4:30 p.m. ET, where they will discuss the results, accessible via the Investor Relations page on their website.
The company specializes in minimally invasive medical devices for treating obesity and metabolic diseases, including the FDA-approved LAP-BAND® System and the investigational ReShape Vest™ System.